News and Reports
 
  - 
  Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics9 November 2020Download
- 
  Galecto Announces Pricing of Initial Public Offering29 October 2020Download
- 
  Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company28 October 2020Download
- 
  Dren Bio Announces a $60M Series A Financing16 October 2020Download
- 
  Cathay Biotech to Invest USD596.5 Million in Northwest China's Largest Synthetic Biology Project12 October 2020Download
- 
  New CEO Joins Karius to Lead Next Growth Phase6 October 2020Download
- 
  Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Ro29 September 2020Download
- 
  Sanofi Completes Principia Biopharma Inc. Acquisition28 September 2020Download
- 
  BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region28 September 2020Download
- 
  Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform24 September 2020Download
- 
  Novellus Closes $57M Series C Financing21 September 2020Download
- 
  Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million16 September 2020Download
- 
  Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing15 September 2020Download
- 
  NiKang Therapeutics Completes $50 Million Series B Financing14 September 2020Download
- 
  Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA8 September 2020Download
- 
  Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics8 September 2020Download
- 
  Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs24 August 2020Download
- 
  Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio24 August 2020Download
- 
  iTeos Therapeutics Announces Pricing of Initial Public Offering23 July 2020Download
- 
  SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors22 July 2020Download
- 
  Bioatla Raises $72.5 Million in Series D Financing15 July 2020Download
- 
  C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-concept and to Advance Proprietary Platform16 June 2020Download
- 
  Viela Bio Announces U.S. FDA Approval of UPLIZNA? (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)11 June 2020Download
- 
  Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease11 June 2020Download
- 
  Everest Medicines Completes US$310 Million Series C Financing4 June 2020Download